U S Wealth Group LLC. Acquires Shares of 7,739 Amgen Inc. (NASDAQ:AMGN)

U S Wealth Group LLC. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 7,739 shares of the medical research company's stock, valued at approximately $2,017,000.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in shares of Amgen by 2.1% in the third quarter. Wellington Management Group LLP now owns 239,354 shares of the medical research company's stock worth $77,122,000 after acquiring an additional 4,942 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Amgen by 10.1% during the 3rd quarter. EP Wealth Advisors LLC now owns 32,852 shares of the medical research company's stock worth $10,585,000 after purchasing an additional 3,024 shares in the last quarter. XTX Topco Ltd raised its holdings in Amgen by 179.1% during the 3rd quarter. XTX Topco Ltd now owns 5,902 shares of the medical research company's stock worth $1,902,000 after buying an additional 3,787 shares during the period. Bontempo Ohly Capital Mgmt LLC lifted its stake in Amgen by 5.2% in the third quarter. Bontempo Ohly Capital Mgmt LLC now owns 8,432 shares of the medical research company's stock valued at $2,717,000 after buying an additional 419 shares in the last quarter. Finally, Dunhill Financial LLC boosted its holdings in shares of Amgen by 5.1% in the third quarter. Dunhill Financial LLC now owns 1,098 shares of the medical research company's stock valued at $354,000 after buying an additional 53 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $4.57 on Friday, hitting $285.98. The company's stock had a trading volume of 3,466,932 shares, compared to its average volume of 2,777,164. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The firm has a market capitalization of $153.76 billion, a P/E ratio of 37.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The stock has a fifty day moving average of $304.33 and a two-hundred day moving average of $295.27. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is presently 126.09%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Truist Financial dropped their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Morgan Stanley boosted their price target on Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday. Citigroup reiterated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler Companies restated an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Finally, UBS Group reaffirmed a "hold" rating on shares of Amgen in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $315.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.